Beate Rau, Charité University of Berlin Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR

Similar documents
Beate Rau, Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR

Beate Rau, Charité Campus Berlin, Berlin, DE Tom Cecil, Basingstoke and North Hampshire Hospital, Basingstoke, UK

Management of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after Cytoreductive Surgery (CRS)

PRELIMINARY PROGRAM. 11 th International Workshop on Peritoneal Surface Malignancy SEPTEMBER 9-11,

International scientific-practical conference «Management of Peritoneal Surfaces Malignancy» Irkutsk, August 9-11, Program

Results of CRS and HIPEC in. Colorectal PSM. and. Pseudomyxoma Peritonei

FINAL SCIENTIFIC PROGRAMME

Patient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201

CURRICULUM VITAE 2005

Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies

Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies

10 th International Congress on Peritoneal Surface Malignancies

Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease. Results of the French multicentric database

Pre-operative assessment of patients for cytoreduction and HIPEC

Colorectal peritoneal metastases and IMPACT

Pseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES

INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION

Results of a French Multicentric Analysis

Management of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Department of Surgery, Kusatsu General Hospital, Yabase Kusatsu 1660, Japan 2

Hepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

CRS e HIPEC: Efficacia e Limiti

HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies

TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS

HIPEC AND COMPLICATED COLORECTAL SURGERY

Peritoneal dissemination is a common manifestation of disease

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY. Ann Surg Oncol (2018) 25:

Wojciech Nowak, Rector of the Jagiellonian University Medical College, Kraków (PL)

Clinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Cancers Reference Number: CP.MP. 346

Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol

Planned relaparotomy following curative resection of a locally advanced gastrointestinal cancer

Surgical Department, Didimotichon General Hospital, Didimotichon, Greece 2

Contents. Part 1. Peritoneal Carcinomatosis: Basic Concepts

Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Specialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for treatment of Pseudomyxoma Peritonei

INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)

Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei

Surgical Oncology, Mercy Medical Center, Baltimore, MD

Gastrointestinal Oncology

POLICIES AND PROCEDURE MANUAL

CRS and HIPEC for Colorectal Cancer. Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017

Clinical Study Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma Peritonei of Appendiceal Origin

Peritonectomy plus hyperthermic peritoneal perfusion for the treatment of peritoneal carcinosis H. Müller, MD, FACS

1. Introduction. Correspondence should be addressed to Horacio N. López-Basave, Received 23 May 2011; Accepted 20 June 2011

Correspondence should be addressed to David Morris; Received 17 February 2013; Revised 14 April 2013; Accepted 24 June 2013

Rationale for the treatment. Peritoneal Surface Malignancy

Welcome Address. Symposium Chairmen. Dear friends and colleagues,

ESSO Advanced Course on UPPER GI Malignancy

Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis

U T C H. No disclosure

ESSO Advanced Course on Primary Liver Tumours

MP Hyperthermic Intraperitoneal Chemotherapy for Select IntraAbdominal and Pelvic Malignancies. Related Policies None

J Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION

tumor. CRS? HIPEC was well tolerated in our selected patients with PC, some of whom had improved survival.

J Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION

is time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the

Corporate Medical Policy

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

Qué operar y que no operar en carcinomatosis peritoneal. Indicaciones y límites.

ESSO-EYSAC Course on Colorectal Cancer Surgery

IJC International Journal of Cancer

Update on the management of malignant peritoneal mesothelioma

Heated Intraperitoneal Chemotherapy (HIPEC) for Advanced Abdominal Cancers

PROGRAM. 13 th ICRCC Congress on Colorectal Cancer Final Programm Friday, 28 September 2018

Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion

Abstract. Materials and methods

Ovarian Tumors. Andrea Hayes-Jordan MD FACS, FAAP Section Chief, Pediatric Surgery/Surgical Onc. UT MD Anderson Cancer Center

Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer

6 TH ESO-SIOP EUROPE MASTERCLASS IN PAEDIATRIC ONCOLOGY June 2016 Berlin, Germany. Chairs: A. Eggert, DE B. Morland, UK R.

Never mistake knowledge for wisdom. One helps you make a living; the other helps you make a life.

GALEN ADVANCED Course

Kathleen A. Cummins 1, Gregory B. Russell 2, Konstantinos I. Votanopoulos 1, Perry Shen 1, John H. Stewart 1, Edward A. Levine 1.

MP Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies

Vic J. Verwaal, MD, PhD, 1 Sjoerd Bruin, MD, 1 Henk Boot, MD, PhD, 2 Gooike van Slooten, MD, 1 and Harm van Tinteren, ScM 3

This is a submitted version of a paper published in European Journal of Surgical Oncology. Access to the published version may require subscription.

Key words: appendiceal carcinoma; peritonectomy; intraperitoneal chemotherapy.

Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies

Hepatobiliary and pancreatic procedures during cytoreductive surgery and HIPEC

Available online at EJSO 37 (2011) 148e154. Accepted 26 October 2010 Available online 18 November 2010

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies

How to deal with patients with isolated peritoneal metastases

Enhanced Recovery after Surgery: Benefits, Challenges and Solutions for Implementation

Saturday, 13 February 2016

Management of Stage IV Colorectal Cancer: Expanding the Horizon

COLON CANCER PERITONEAL CARCINOMATOSIS TREATMENT Prof. Annibale Donini

SIOP. 7 TH ESO-SIOP EUROPE MASTERCLASS IN PaEDiatRic OncOlOGy June 2018 nauen Ot Groß Behnitz (Berlin area), Germany.

Ascites and malnutrition are predictive factors for incomplete cytoreductive surgery for peritoneal carcinomatosis from gastric cancer

Hyperthermic Intraperitoneal Chemotherapy

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal carcinomas with peritoneal carcinomatosis

Computerized System for Staging Peritoneal Surface Malignancies

4th ESSO Advanced Course on the Management of Colorectal Liver Metastases

LUMINAL IMAGING GROUP. Department of Radiology, Mayo Clinic, Rochester, MN 2. Department of Radiology, Mayo Clinic, Scottsdale, AZ 3

Current standard in treatment of peritoneal carcinomotisis. Data behind the HIPEC trials

Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer

Clinical Study Adjuvant Perioperative Intraperitoneal Chemotherapy in Locally Advanced Colorectal Carcinoma: Preliminary Results

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Short bowel syndrome after cytoreductive surgery and HIPEC: nutritional considerations

Treatment-related post-operative mortality after cytoreductive surgery and perioperative intraperitoneal chemotherapy

Transcription:

Chairs Beate Rau, Charité University of Berlin Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR Faculty members Frédéric Bibeau, Caen University Hospital, Caen, FR Andreas Brandl, Charité Campus Berlin, Berlin, DE Marcello Deraco, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT Roland Francis, Charité Campus Berlin, Berlin, DE Olivier Glehen, Centre Hospitalier Lyon-Sud, Pierre Bénite, Lyon, FR Gabriel Glockzin, Klinikum Bogenhausen, Munich, DE Santiago González-Moreno, Centro Oncológico MD Anderson, Madrid, SP Chirsthardt Köhler, Asklepios Klinik, Hamburg, DE Rea Lo Dico, Lariboisière Hospital, Paris, FR Faheez Mohamed, Basingstoke and North Hampshire Hospital, Basingstoke,UK Markus Möhler, Stéphanie Nougaret, Institut Régional du Cancer de Montpellier, Montpellier, FR Pompiliu Piso, St John and God Hospital, Regensburg, DE Marc Pocard, Lariboisière Hospital, Paris, FR/Paris Diderot 7 University, Paris, FR Emmanuelle Samalin, Institut Régional du Cancer de Montpellier, Montpellier, FR Olivia Sgarbura, Institut Régional du Cancer de Montpellier, Montpellier, FR Marianne Sinn, Charité Campus Berlin, Berlin, DE Paul Sugarbaker, Washington Cancer Center, Washington, US Kurt Van der Speeten, Ziekenhuis Oost-Limburg, Genk, BE Willemien van Driel, Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, NL Vic Verwaal, Aarhus University Hospital, DK

Programme Thursday 15 th February 13:00 Introduction B. Rau Treatment principles for Peritoneal Surface Malignancies: surgical approach and clinical pathological pathway - Chairs: B. Rau, F. Quenet 14.00 14.30 Techniques of cytoreductive surgery with peritonectomy procedures (CRS) P. Sugarbaker 14.40 15.00 Video technique CRS from Regensburg P. Piso 15.10 15.25 Pharmacology of different techniques of intraperitoneal drug administration; role of heat and carriers K. Van der Speeten 15.30 15.40 The role of laparoscopy in PSM M. Pocard 15.45 15.55 Preoperative staging in peritoneal metastases: necessary and nice to have (morphologic exams and peritoneal carcinomatosis) S. Nougaret 16.00 16.30 Coffee break Perioperative management Chairs: M. Pocard, P. Piso 16.30 16.40 Patient selection for CRS and HIPEC V. Verwaal 16.45 16.55 OR personnel safety related to HIPEC A. Brandl 17.00 17.10 To speak the same language: PCI, CCR and PSS G. Glockzin 17.15 17.25 Perioperative management of CRS and HIPEC: view of the anaesthesiologist R. Francis

17:30 17.40 Prevention and management of postoperative surgical complications M. Pocard 17.45 17.55 Overview of international guidelines for CRS and HIPEC S. Santiago González-Moreno 18.00 18.10 How to start a new center for the treatment of PSM M. Pocard Friday 16 th February Hands on session Tutors: M. Deraco, O. Glehen, G. Glockzin, S. González-Moreno, P. Piso, C. Köhler, F. Quenet, O. Sgarbura,Andreas Brandl, M. Pocard, S. Nougaret, R. Lo Dico, B. Rau, P. Sugarbaker, K. Van der Speeten, V. Verwaal,, F. Mohamed 08:30 08.40 Anatomical structure in animal L. K. Groebler 08.40 08.50 Debriefing from human to animal B. Rau 09.00 11.00 Right upper abdomen Right Abdominal wall Interenteric Right Diaphram arcus tendineum Resection gastric surface Bursa omentalis Splenectomy Pancreatic tail resection 11.00 11.30 Coffee Break 11.30 12.30 Left upper abdomen Left abdominal wall Left diaphragm arcus tendineum Resection of serosal surface of bowel mesenterium Hepatoduodenal ligament Cholecystectomy Resection of small bowel Triangle ligament Morrison pouch

12.30 13.30 Lunch 13.30 14.00 Pelvic Resection of omentum Resection of serosal surface of bowel Resection of peritoneal surface of the bladder Lymph node preparation central mesenterical route 14.00 15.00 Devices HIPEC open and Devices HIPEC close 15.00 15.30 Coffee Break Gastric cancer (debate) Chairs V. Verwaal, A. Brandl 15.30 15.40 Prophylactic HIPEC in gastric cancer: pro O. Glehen 15.45 15.55 Prophylactic HIPEC in gastric cancer: contra M. Möhler 16.00 16.10 CRS and HIPEC in peritoneal metastatic gastric cancer: pro B. Rau 16.15-16.25 CRS and HIPEC in peritoneal metastatic gastric cancer: contra M. Möhler Young surgeons video master class 16.25 16.32 Pseudomyxoma Moderator: F. Mohamed 16.35 16.42 Colorectal cancer Moderator: V. Verwaal 16.45 16.52 Gastric cancer Moderator: O. Glehen 16.55 17.02 Ovarian cancer Moderator: C. Köhler 17.05 17.12 Mesothelioma Moderator: M. Deraco

17.15 17.22 Rare cancer sites Moderator: S. González-Moreno 17.25 17.45 Discussion with the experts Saturday 17 th March Frequent indications and systemic treatment: what is new Update Chairs: M. Deraco, S. González-Moreno 08.30 08.50 Pseudomyxoma Peritonei F. Mohamed 08.50 09.10 Malignant Peritoneal Mesothelioma and Primay Peritoneal Carcinoma M. Deraco 09.10 09.30 Peritoneal Metastases from Ovarian Cancer W. J. van Driel Discussion with the experts Chairs: K. Van der Speeten, M. Pocard 09.30 09.45 CRS and HIPEC video M. Deraco 09.45 09.55 Ovarectomy per principle? C. Köhler 09.55 10.05 Splenectomy per principle? A. Brandl 10.05 10.15 Critical technical points in upper abdomen O. Sgarbura 10.15-10.45 Coffee Break Peritoneal metastases from colorectal cancer: debate Chairs: I. de Hingh, F. Mohamed 10.45 10.55 CRS on patients with extra peritoneal metastases in CRC: pro R. Lo Dico

10.55 11.05 CRS on patients with extra peritoneal metastases in CRC: contra E. Samalin 11.05 11.20 Treatment options in in peritoneal metastases from colorectal origin: the medical oncology point of view M. Sinn 11.20 11.35 Peritoneal Metastases from Colorectal Cancer (particularities of CRS, HIPEC and CCR score) results of the trial F. Quenet 11.35 11.50 Importance of pathologic response F. Bibeau 11.50 12.05 What is new about PIPAC in gastric and colorectal cancer O.Sgabura 12.05 12.30 Conclusions